Bacterial pyoderma is more common in the dog than any other mammalian species. Currently Staphylococcus virulence factors such as protein A, leukocidin, hemolysins, epidermolytic toxin have not been shown to be to play a role in canine pyoderma as opposed to humans with Staphylococcus aureus infections.
Bacterial pyoderma is more common in the dog than any other mammalian species. Currently Staphylococcus virulence factors such as protein A, leukocidin, hemolysins, epidermolytic toxin have not been shown to be to play a role in canine pyoderma as opposed to humans with Staphylococcus aureus infections. Studies have been unable to identify differences in toxin profiles were found between Staphylococcus from normal dogs and dogs with pyoderma. Because Staphylococcus intermedius is a normal commensal of the dog it appears that abnormal "host factors" are an important cause of pyoderma in dogs. These include hypersensitivities, endocrinopathies and cornification abnormalities.
Pyodermas can be classified based on the depth of the lesion(s). The different classifications are:
1. Pyotraumatic dermatitis
2. Mucocutaneous pyoderma
3. Skin fold dermatitis
Superficial bacterial folliculitis (SBF)
1. Deep folliculitis and furunculosis
2. Cellulitis (SQ involvement)
Pyotraumatic dermatitis is diagnosed based on the appearance of the lesions (alopecia, crusts, and erosions +/- pain) with a history of a peracute onset. Treatment for this lesion is sedation, clipping and scrubbing the lesion(s) gently with a chlorhexidene based shampoo. This is followed by an injection of dexamethasone (2 mg/ml) – 2 mg/30# SQ and dispensing topical therapy using a moderately potent antibiotic/steroid cream (Panolog) bid for 5-10 days along with continued (gentle) cleansing of the lesion. IDENTIFY and treat/eliminate (if possible) the underlying cause (flea allergy dermatitis (FAD), environmental allergen induced atopic dermatitis (atopy) or cutaneous adverse food reactions (CAFR). Please note that Golden Retrievers and Saint Bernards have a unique form of a pyotraumatic dermatitis involving the cheeks. This cheek "pyoderma" is NOT a surface pyoderma but rather a deep folliculitis and furunculosis and needs aggressive antibiotic therapy for 30 days along with an e –collar to prevent self-trauma- NOT steroids!
Mucocutaneous pyoderma (the author feels a better name is "antibiotic responsive dermatitis" since bacteria are not seen histologically) is a crusting disease that may affect the lips, nasal planum (exclusively), the bridge of the nose, periocular region, genitals or anus. Clinically it is indistinguishable from DLE. There is no identifiable cause for this disease and the diagnosis is based on the signalment (adult dog, most commonly in German Shepard Dogs (or mixes)), clinical appearance and distribution of the lesions and most importantly response to antibiotic therapy. In the past it was differentiated from DLE based on histopathologic findings. DLE was diagnosed when a lichenoid lymphocytic to lymphoplasmacytic interface dermatitis with hydropic degeneration and/or individual necrotic keratinocyte involving the basal cell layer, pigmentary incontinence and a thickened basement membrane was present. Mucocutaneous pyoderma would be diagnosed histologically when a lichenoid plasmacytic to lymphoplasmacytic infiltration was present without an interface change and without basal cell damage. HOWEVER, this criterion has been called into question with a recent study that reported that histologically mucocutaneous pyoderma and DLE may be indistinguishable! In that study, dogs were separated, based on histologic findings, into 3 groups, ones with lymphocytic lichenoid interface dermatitis with hydropic degeneration; ones with plasmacytic lichenoid dermatitis, and lastly ones with a mixture of the first 2 patterns- lymphoplasmacytic lichenoid, interface dermatitis with hydropic degeneration. The authors then evaluated whether the group responded to antibiotics or immunomodulating therapy. There was no statistical difference when histopathologic features were compared between the 2nd and 3rd groups! The author now believes that all cases of canine nasal dermatitis should have a 30 day course of cephalexin prior to immunomodulating therapy- in fact prior to biopsy a 3-4 week course of a cephalosporin is appropriate and may establish a diagnosis without needing to biopsy the lesion!
Impetigo is a NON-follicular surface pyoderma seen most commonly in puppies between 6 weeks and 4 months of age. This lesion is usually found as an incidental finding during a routine vaccination visit. An underlying cause is rarely identified but the puppy should be evaluated for intestinal parasites and the diet and environment of the puppy should be reviewed and changed if necessary. Diagnosis is based on signalment, clinical appearance and distribution of the lesions and response to topical +/- systemic antimicrobial therapy. If systemic antibiotics are used they should used for 10-14 days passed clinical resolution of the lesions. Many times just an antimicrobial shampoo (containing chlorhexidene) +/- a topical antimicrobial residual product (chlorhexidene containing spray or leave on conditioner or a Mupirocin containing ointment) for 10-14 days is sufficient.
Superficial bacterial infection of the hair follicle (folliculitis) (SBF) is the most common presentation for dogs with a bacterial skin infection. Staphylococcus intermedius and, less commonly, Staphylococcus aureus have been the most commonly isolated pathogens in dogs with SBF. To confuse matters, the microbiologist now state that all the organisms identified in the past as Staphylococcus intermedius are really Staphylococcus pseudintermedius. This name change is not really clinically important since the treatment, etc are the same. But it is important that you are aware of this name change so that you are not confused in reading current literature. In fact you may see the term Staphylococcus intermedius group- just be aware it encompasses S. intermedius, S. pseudintermedius, and Staphylococcus delphini. Again this change is not clinically relevant.
Recently another Staphylococcus organism has been associated with bacterial pyoderma. This staphylococcus - Staphylococcus schleiferi may be either coagulase positive (Staphylococcus schleiferi coagulans) or coagulase negative Staphylococcus schleiferi (schleiferi). In the past coagulase negative Staphylococcus were consider contaminants if identified on a culture. However coagulase negative Staphylococcus schleiferi (schleiferi) is a potential pathogen and also is potentially zoonotic. Because of this it is important that laboratories identify coagulase negative Staphylococcus down to the species level (to ddx nonpathogenic S. epidermidis from pathogenic Staphylococcus schleiferi).
Dogs with SBF may be non-pruritic or pruritic (from mild to intensely). Clinically SBF appears differently in different breeds of dogs. Most dogs will have multifocal areas of alopecia, follicular papules or pustules, epidermal collarettes, and serous crusts involving the trunk, abdomen and axillary areas. Short-coated breeds often present with a moth eaten appearance to the hair coat due to multiple superficial follicular papules. Clinically these dogs will appear similar to dogs with urticaria. These may be the only lesions present. Cocker Spaniels have their own special presentation, vegetative plaques. These plaques are frequently mistaken for seborrheic plaques. Clinically and histologically they can be quite similar, so if plaques are found in a Cocker, the dog should be treated for a bacterial pyoderma before condemning the dog to "idiopathic seborrhea". The diagnosis of SBF is usually based on clinical signs—alopecia, papules, pustules, and epidermal collarettes. Differential diagnoses for lesions (follicular papules) that resemble SBF include demodicosis, Malassezia dermatitis and dermatophytosis. If non-follicular papules, add insect bites to the differential diagnosis list. If epidermal collarettes or pustules are present pemphigus foliaceus should be considered.
Primary lesions seen in deep bacterial pyoderma include nodules, hemorrhagic bullae, and draining tracts consisting of a serosanguineous to purulent exudate. Distribution of these lesions includes the bridge of the nose, chin, elbows, hocks and interdigital areas. In some dogs lesions may also include the lateral stifles or the trunk. Acral lick dermatitis is a subset of deep pyodermas usually affecting the carpus, metacarpus or metatarsal regions.
Any time a pyoderma is diagnosed in a dog it is essential that you approach the problem in a systematic manner but this is especially true for SBF and deep pyodermas. It is critical to remember that there is NO such thing as a primary bacterial pyoderma in the dog- you must always remember that it is "due to" something else. A dog presented for the first time with a SBF may only need to have a limited number of diagnostic tests performed while a recurrent or chronic case of SBF or ANY dog with a deep bacterial pyoderma will need to have the underlying cause aggressively pursued. Causes of SBF (deep pyoderma causes are marked with an *) include
1. Hypersensitivities (atopy; cutaneous adverse food reactions; FAD)
2. * Endogenous (hyperadrenocorticism) or exogenous steroid exposure;
3. * Demodicosis;
4. * Hypothyroidism;
5. Follicular dysplasias (eg color dilution alopecia, Chinese crested dogs);
6. Cornification abnormalities (sebaceous adenitis, ichthyosis)
In approaching a dermatologic case, the first step is to review the signalment. Age and breed can help point you in the right directions.
The next step may be the most important one, obtaining a detailed history! This starts by getting a copy of the dog's medical record. If the dog has had previous skin or ear disease, getting a copy of the medical records may help tremendously in developing a differential diagnosis list. Questioning the owner can help pinpoint the primary cause of the pyoderma. Questions that should be asked include:
1. Distribution of lesions initially and currently.
2. When did these symptoms first occur?
3. Has the dog had previous ear or skin disease before and if so when did it occur and how was it treated?
4. Where does the dog live- indoor, outdoors, both?
5. Which, if any heartworm and flea preventative is being used and how is it used
6. Are there any other pets in the household? If so, what kind and are they symptomatic.
7. Are any of the humans in the household showing "new" skin problems? If so, what kind
8. Do they board the dog, take him to obedience school, training or to the groomers?
9. What does the dog eat?
10. Is the dog pruritic
11. Is today's clinical presentation the best, worse or average since the problem began?
12. How was the progression of the lesions? Gradual or sudden?
13. If the dog is pruritic was there a "rash" first or itching first? Or did they occur simultaneously?
After reviewing signalment and thoroughly questioning the owner, the next step is to do a complete physical exam.
After your examination you should have a list of differential diagnoses for the underlying cause of the SBF (or a deep pyoderma) in the patient. ALL dogs with lesions consistent with SBF or deep pyoderma need to have deep skin scrapings performed for to identify demodex mites if present. More recently a superficial demodectic mite has been identified in dogs- Demodex cornei. This short-bodied canine mite inhabits the surface layer of the skin as does the similar Demodex gatoi of cats. The biology of this new canine mite and its pathogenesis is poorly defined. It has been associated with pruritic dermatitis. An impression smear of a lesion should be evaluated for infectious agents, inflammatory cells and acantholytic keratinocytes (found in pemphigus foliaceus pustules). Dermatophyte cultures should be considered depending on the signalment, distribution of the lesions and the extent of the lesions.
Culture and susceptibility testing should be performed on poorly responsive (NOT recurrent) SBF. If a deep pyoderma has exclusively rods on cytology, has been treated with antibiotics recently or the dog is systemically ill then a culture and susceptibility test should be performed. If a c/s is submitted, the MIC (broth microdilution technique) method should be used to determine the susceptibility rather than the disc diffusion method (Kirby-Bauer). The disk-diffusion susceptibility test (DDST) is semiquantitative in that the drug concentration achieved in the agar surrounding the disc can be roughly correlated with the concentration achieved in the patient's serum. It will only report the organism's susceptibility (susceptible, intermediate or resistant) based on an approximation of the effect of an antibiotic on bacterial growth on a solid medium. Tube dilution (MIC) is quantitative, not only reporting SIR but also the amount of drug necessary to inhibit microbial growth. This allows you to not only decide susceptible or resistant but also the proper dosage and frequency of administration of the antibiotic. Please be aware that a susceptible designation alone does not necessarily imply efficacy. The advantage of the MIC method is that not only does it indicate susceptibility, but it also implies the relative risk of emerging resistance and thus the need for a high dose.
Samples from a pustule or intact nodule should be used for culturing however, if an intact pustule is not available culturing an epidermal collarette has also been shown to be reliable for sampling a SBF while using a minitip culturette to sample deep into a draining tract or a macerated tissue sample are acceptable for deep pyodermas.
In the past oxacillin was used to identify all methicillin resistant Staphylococcus. If the Staphylococcus was resistant to methicillin (MRS) then it would be resistant to ALL of the beta lactams. The new protocol for humans is to use cefoxitin to identify MRS. In humans the organism is Staphylococcus aureus. The problem is that in animals the Staphylococcus infectious usually belongs to the Staphylococcus intermedius group (S. intermedius, S. pseudintermedius, and Staphylococcus delphini) and certain strains of methicillin-resistant S pseudintermedius (any in the SIG?) may be falsely identified as methicillin susceptible if the laboratory uses cefoxitin susceptibility as the indicator. This is because cefoxitin may not induce the mecA gene as reliably in S pseudintermedius as it does in Staphylococcus aureus. It is currently recommended that oxacillin susceptibility testing should be retained for S pseudintermedius isolates (all SIG?) How is this clinically important? If you are using a human laboratory or a local laboratory they may not be aware of this difference between Staphylococcus aureus and SIG testing. Because of this I would strongly recommend using a veterinary laboratory that uses Clinical and Laboratory Standards Institute (CLSI) guidelines AND is aware of and has current knowledge of veterinary pathogens
Recently the effectiveness of clindamycin against MRSA has been questioned. There are 2 genes, msrA and the erm that are responsible for S.aureus' resistance to macrolides (eg erythromycin). The msrA gene accounts for the resistance to only macrolides, while the erm gene codes for macrolides and lincosamides (lincomycin and clindamycin) resistant. The erm gene may be constitutive which means that it will be present in the bacteria from the onset and the culture will report resistance to clindamycin. It may be inducible in which case the MRSA will be initially susceptible to clindamycin and therefore reported as such. When MRSA has the inducible gene resistance to clindamycin will develop WHILE on treatment. As the susceptibility pattern to clindamycin of MRSA isolates possessing msrA gene (truly susceptible to clindamycin) or the inducible erm gene (potentially resistant) are the same, it is important to distinguish between these phenotypes. This is accomplished by an additional culture technique called the Double-disc diffusion D-test. This test will detect the occurrence of the inducible erm gene. Since no commercial lab is currently doing this additional culture, resistance to erythromycin may be used as a clue to this inducible gene. This is because the msrA gene and the erm gene both encode Staphylococcus resistance to erythromycin. So if the Staphylococcus is resistant to erythromycin, there is a potential for the presence of the inducible erm gene. In a recent study, 97.3% of erythromycin-resistant isolates of MRSA were truly resistant to clindamycin despite only 25.5% demonstrating clindamycin resistance by routine laboratory testing. Therefore it would prudent to avoid clindamycin on all Staphylococcus aureus infections that report resistance to erythromycin. However in a recent study inducible clindamycin-resistance was present in only MRSA isolates NOT in MRSP. It was concluded that since inducible resistance was not identified in MRSP the use of clindamycin is reasonable option.
Because of the increasing incidence of resistant bacterial infections to orally administered antibiotics, topical therapy either as a monotherapy or as part of polypharmacy is critical. Topical therapy not only may decrease or eliminate the need for systemic antibiotics but since many of the dogs with SBF have atopic dermatitis, bathing to remove antigens from the skin can be useful in managing the allergies. The limitations of using topical therapy include time constraints of the owner and if treating a large area, cost may be significant. Shampoo ingredients that are effective for treating bacterial pyoderma include chlorhexidene, boric acid/acetic acid, benzoyl peroxide, ethyl lactate and triclosan with the later 2 being less effective than the others.
Topical therapy with mupirocin is very useful. Not only is it a very effective antimicrobial agent against gram positive bacteria but because of its unique MOA cross-resistance with other antibiotics is very uncommon
Silver Sulfadiazine has traditionally been used for its effectiveness against gram negative bacteria, especially Pseudomonas. However it is also effective against some gram-positive bacteria
When treating a dog with a SBF use an antibiotic for at least 21 days, or 14 days past YOUR clinical examination that the infection has resolved, whichever is LONGER. For dogs with deep pyoderma, treat for at least 6 weeks or 21 days beyond clinical resolution, whichever is longer. In SBF don't use GC for cases where the pruritus is only at the lesions or when the pruritus is only mild at the nonlesional areas. If a dog with a SBF has intense pruritus at nonlesional areas then a tapering 21 days course of prednisone may be dispensed. Using GC in the presence of a pruritic pyoderma makes interpretation of response to therapy impossible (was it the steroid or the antibiotic/antifungal therapy that resolved the pruritus?). It also makes it more difficult to resolve the infection. NEVER use GC in deep pyodermas!!
In regards to systemic antibiotic the following are appropriate skin antibiotics
1. Cephalexin 10-15 mg/# bid-tid
2. Cefpodoxime proxeil- Simplicef® - 5-10 mg/kg sid
3. Clindamycin- Antirobe® 5-10 mg/# sid-bid
4. Amoxicillin/clavulanic acid – Clavamox® 10 mg#/bid
5. Trimethoprim/sulfonamide- Tribrissen® 10-15 mg/# bid
6. Cefovecin (Convenia)- SOMETIMES
Cefpodoxime (Simplicef®, Pfizer) is a 3rd generation cephalosporin effective for most of the Staphylococcus infections that occur in dogs. This once a day antibiotic is useful in cases where the owner has difficultly administering capsules not only because it is once a day but it seems that these pill are easier to give. When doing a food trial it is best to avoid gelatin (animal protein) so that giving cefpodoxime tablets would fill this need. Also it seems like there is less GI disturbances than there is w/cephalexin. An additional reason to dispense Simplicef is the veterinary drug companies must be supported so that they have the resources to continue R &D. However consider when dispensing cefpodoxime there are some Staphylococcus infections that will be resistant to cefpodoxime but susceptible to cephalexin. Also the supposed advantage that a once a day treatment may not be such- a study revealed there is no difference in compliance w/sid vs. bid. Lastly there are numerous studies showing that sid cephalexin at 30-40 mg /kg sid is as effective as splitting this dose, however this is NOT my recommendation but that missing 1dose of cephalexin is not catastrophic. Also see comments about 3rd generation cephalosporin use below.
Cefovecin (Convenia®, Pfizer) is a parenterally administered 3rd generation cephalosporin that will be of tremendous value when used selectively. I feel that for now this drug should be reserved for cases where the owner is unable to medicate the dog or cat. I am concerned that I that therapeutic drug concentrations after the first injection are maintained for only 7-14 days depending on the infectious agent while tissue levels persist for up to 65 days. The question is whether this prolonged subtherapeutic blood (tissue?) level will encourage the incidence of methicillin resistant Staphylococcus. Will adverse reactions require prolonged treatment due to the prolonged systemic drug clearance? What are the long-term effects on injection sites especially in cats? How clinically significant is the in vitro finding that cefovecin increases free concentrations of carprofen, furosemide, doxycycline, and ketoconazole. Will drugs w/a high degree of protein-binding (e.g. cardiac, anticonvulsant, and behavioral medications) compete enough with cefovecin-binding to adverse reactions.
In regards to 3rd generation cephalosporins and any fluoroquinolones, in the BSAVA Guide to the Use of Veterinary Medicines, prudent use of antimicrobial agents it is stated that in all species fluoroquinolones and third- and fourth-generation cephalosporins should be used judiciously and never considered as first-choice options.
Also the European Medicines Agency states (EMEA/CVMP/215997/2006) "Following advice given by the CVMP Scientific Advisory Group on Antimicrobials (SAGAM), the CVMP agreed the following statements should be included in section 4.5 of the SPC (special precautions for use) "It is prudent to reserve third generation cephalosporins for the treatment of clinical conditions, which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials or first generation cephalosporins." and "Use of the product should be based on susceptibility testing and take into account official and local antimicrobial policies".
Summary- if the dog has papules, pustules and/or epidermal collarettes then deep skin scrapings, skin cytology +/- fungal culture should be performed. Antibiotics and shampoo therapy are prescribed as mentioned below. Recheck the dog after 14-21 days of antibiotics to access response. Treat any identified underlying disease.
1. Antibiotics- Remember for SBF 21 days is the minimum and 6 weeks is the minimum treatment time for dogs with deep pyoderma. Use an appropriate skin antibiotic as previously listed.
a. Reasons NOT to use fluoroquinolones in SBF are:
i. Information from the CDC website- "that none of the fluoroquinolones are FDA-approved for treatment of MRSA infections. A major limitation of fluoroquinolones is that resistant mutants can be selected with relative ease, leading to relapse and treatment failure. MRSA strains are especially adept at developing fluoroquinolone resistance, and such resistance is already found among MRSA isolated from patients with CA-MRSA infections
ii. Because the incidence of MRSA is associated with fluoroquinolone usage
b. My initial antibiotic will be cephalexin.
iii. If there is no response to the initial appropriate anti-Staph antibiotic, given at an appropriate dose and frequency, then culture and susceptibility testing should be performed. Pending results the author will dispense clindamycin 5-10 mg/# bid if it has not already been used.
2. Antimicrobial +/- antifungal shampoo is helpful
If the dog was pruritic along with the SBF and the pruritus and lesions resolve when you have only treated the secondary infections continue the antibiotic for 14 more days. In this case the SBF was the major cause of the CURRENT pruritus (was only symptomatic when the secondary infection was present – "threshold theory") and it was secondary to one of the following:
c. Seasonal atopy and the season has changed;
d. An endocrinopathy
If the dog was pruritic with the SBF and the pruritus did NOT resolve with antibiotics but the lesions did, then continue the antibiotic for 14 more days. Atopy, CAFR or ectoparasites need to be pursued as the underlying cause in this situation.
If the dog was pruritic with the SBF and the pruritus and lesions did NOT resolve with antibiotics, ectoparasiticidal therapy, fungal culture and bacterial culture and susceptibility testing should be performed (and/or biopsy). Pending results the author will dispense clindamycin 5-10 mg/# bid
If the dog was NOT pruritic in the face of the SBF then either the dog has seasonal atopy and the season has changed or the dog has an endocrinopathy. Rarely CAFR or nonseasonal atopy may present with recurrent non-pruritic SBF. If the lesions resolve with antibiotics then continue the antibiotics for 14 more days and continue to investigate the underlying cause. If the lesions DON'T resolve with antibiotics then fungal culture and bacterial culture and susceptibility testing should be performed (and/or biopsy). Pending results the author will dispense clindamycin 5-10 mg/# bid.
Unfortunately there will be cases of recurrent SBF that have been properly worked up and managed. In recurrent cases with no definable cause the author will treat with antibiotics for a minimum of 6 weeks and begin immunotherapy with Staph Phage Lysate (SPL) (Delmont Labs, Swarthmore, PA, USA). However the following criteria need to be met to maximize the success of SPL
1. The disease responds to antibiotic and topical antimicrobial therapy ALONE (NO steroids have been used)
2. The dog should have a history of recurrent SBF that has been treated appropriately (14 days past clinical resolution – minimum of 21 days)
3. All underlying causes should be ruled out (i.e., demodicosis, flea allergy dermatitis, CAFR, hyperadrenocorticism (iatrogenic and spontaneous) and hypothyroidism).
If in spite of these therapies the SBF continues to recurrent the author will "admit defeat" and treat with a long term, low dose antibiotic therapy. The risk with this treatment is the possibility of developing a resistant infection, even though this has not been recognized in cases managed by the author in this manner.
Allaker RP, Lamport AI, Lloyd DH, et al. Production of "virulence factors" by Staphylococcus intermedius isolated from cases of canine pyoderma and healthy carriers. Microbial Ecology in Health and Disease 1991; 4: 169-73.
Ihrke PJ. Bacterial Skin Disease in the Dog--A Guide to Canine Pyoderma. Bayer/Veterinary Learning Systems, 1996.
Wiemelt SP, Goldschmidt MH, Greek JS et al. Clinical and histopathological features of nasal dermatitis in dogs. 18th Proceedings of the American Academy of Veterinary Dermatology/American College of Veterinary Dermatology Meeting, Monterey, California, 2003:191.
Mason IS, Lloyd DH. The role of allergy in the development of canine pyoderma. Journal of Small Animal Practice. 1989; 30: 216-8.
Chesney, C.J., 2002. Food hypersensitivity in the dog: a quantitative study. Journal of Small Animal Practice 43, 203-207
Kwochka KW. Recurrent pyoderma in Griffin CE, Kwochka KW, MacDonald JM ed. Current Veterinary Dermatology. The science and art of therapy. St Louis, Mosby Year Book. 1993; 3-21.
Scott DW, Miller WH, Griffin CE. Muller and Kirk's Small Animal Dermatology 6th ed. Philadelphia, WB Saunders Company, 2001, p 230-232, 274-335, 647-650.
Mason IS, Lloyd DH. The role of allergy in the development of canine pyoderma. Journal of Small Animal Practice. 1989; 30: 216-8.
Devriese L., Vancanneyt M., Baele M, et al Staphylococcus pseudintermedius sp. nov., a coagulase-positive species from animals. International Journal of Systematic and Evolutionary Microbiology. 2005; 55: 1569-73.
Morris DO, Rook KA, Shofer FS, Rankin SC. Screening of Staphylococcus aureus, Staphylococcus intermedius, and Staphylococcus schleiferi isolates obtained from small companion animals for antimicrobial resistance: a retrospective review of 749 isolates (2003-04). Veterinary Dermatology. 2006; 17: 332-7.
Loeffler A, Linek M, Moodley A, et al. First report of multiresistant, mecA-positive Staphylococcus intermedius in Europe: 12 cases from a veterinary dermatology referral clinic in Germany. Veterinary Dermatology. 2007; 18: 412-21.
Bemis DA, Jones RD, Hiatt LE, et al. Comparison of tests to detect oxacillin resistance in Staphylococcus intermedius, Staphylococcus schleiferi, and Staphylococcus aureus isolates from canine hosts. Journal of Clinical Microbiology. 2006; 44: 3374-6.
Weese JS, Faires M, Brission BA, et al. Infection with methicillin-resistant Staphylococcus pseudintermedius masquerading as cefoxitin susceptible in a dog- JAVMA, Vol 235, No. 9, November 1, 2009
Jones RD, Kania SA, Rohrbach BW et al. Prevalence of oxacillin- and multidrug-resistant staphylococci in clinical samples from dogs: 1,772 samples (2001-2005). Journal of the American Veterinary Medical Association. 2007; 230: 221-7.
Faires MC, Gard S, Aucoin, et al Inducible clindamycin-resistance in methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius isolates from dogs and cats Veterinary Microbiology 139 (2009) 419–420
Loh JV, Percival SL, Woods EJ, et al, Silver resistance in MRSA isolates from wound and nasal sources in humans and animals Int Wound J 2009, 6:32-8
Pfizer drug insert – prescribing information for Convenia
Six R, Cherni J, Chesebrough R, et al. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. -. 2008 Aug 1;233(3):433-9
Dancer SJ: The effect of antibiotics on methicillin-resistant Staphylococcus aureus Journal of Antimicrobial Chemotherapy (2008) 61, 246–253
Rankin SC, O'shea K, Morris DO:Susceptibility of companion animal isolates of Staphylococcus schleiferi to cephalothin and cefpodoxime Vet Derm: 17:3; 214
Adams VJ, Campbell JR, Waldner CL et al: Evaluation Of Client Compliance With Short-Term Administration Of Antimicrobials To Dogs. J Am Vet Med Assoc. 2005 Feb 15;226(4):567-74.
Toma S, Colombo S, Cornegliani L, et al: Efficacy And Tolerability Of Once-Daily Cephalexin Canine Superficial Pyoderma: An Open Controlled Study J Small Anim Pract2008 49(8):384-91.
Cadot P., Salomon, C., Carlotti, DN.:Treatment Of Superficial Pyoderma In Dogs: Cephalexin In A Single Dose Versus Marbofloxacin. Proceedings 26th World Veterinary Congress WVA. Lyon, France, September 1999.
Maynard L, Guague E, Medaille, C.: Clinical Efficacy Of Cephalexin Administered Once Or Twice Daily By Oral Route In The Treatment Of Superficial Pyoderma In Dogs. Proceedings 18th ESVD Congress. Nice, France, September 2002:
Maynard L, Guague E, Medaille, C The Treatment Of Superficial Pyoderma in Dogs. Proceedings 18th ESVD Congress. Nice, France, September 2002: 198
Intorre L, Vanni M, Di Bello D, Pretti C, Meucci V, Tognetti R, Soldani G, Cardini G, Jousson O. Antimicrobial susceptibility and mechanism of resistance to fluoroquinolones in Staphylococcus intermedius and Staphylococcus schleiferi. Journal of Veterinary Pharmacology and Therapeutics. 2007; 30: 464-9.
DeBoer DJ, Moriello KA, Thomas CB, Schultz KT. Evaluation of a commercial staphylococcal bacterin for management of idiopathic recurrent superficial pyoderma in dogs. American Journal of Veterinary Research. 1990, 51: 636-9.
Curtis CF, Lamport AI, Lloyd DH. Masked, controlled study to investigate the efficacy of a Staphylococcus intermedius autogenous bacterin for the control of canine idiopathic recurrent superficial pyoderma. Veterinary Dermatology. 2006; 17: 163-8.